Click here to view the original post by Healio Ophthalmology.
In addition to our own original articles, the Retina Consultant team expertly curates relevant news and research from leading publications.to provide our readers with a comprehensive view of the retina & ophthalmology landscape, Full credit belongs to the original authors and publication.
By clicking the link above, you will be leaving our site to view an article from its original source.
Sharpen your perspective. Get our weekly analysis of the news shaping the retina industry.
Life Biosciences plans to begin human clinical trials of a cellular rejuvenation therapy in optic neuropathies after receiving FDA clearance of an investigational new drug application, according to a press release.
ER-100 aims to modify the epigenome of cells to restore injured cells without changing their underlying DNA sequence, according to the release.
“For eye care providers, ER-100 represents a fundamentally new approach to treating optic neuropathies as it targets retinal ganglion cell health rather than focusing on downstream factors such as intraocular pressure,” Sharon